MO
Get informed when a big investor buys or sells
+ FollowApril 30, 2026 - AI Summary
Undervalued by 32.4% based on the discounted cash flow analysis.
| Market cap | $116.19 Billion |
|---|---|
| Enterprise Value | $137.26 Billion |
| Dividend Yield | $4.20 (6.04%) |
| Earnings per Share | $4.11 |
| Beta | 0.52 |
| Outstanding Shares | 1,673,000,000 |
| P/E Ratio | 14.46 |
|---|---|
| PEG | 14.08 |
| Price to Sales | 5.42 |
| Price to Book Ratio | -35.2 |
| Enterprise Value to Revenue | 6.29 |
| Enterprise Value to EBIT | 11.96 |
| Enterprise Value to Net Income | 17 |
| Total Debt to Enterprise | 0.18 |
| Debt to Equity | -7.66 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.8198▼ 10.76% |
|---|---|
| Total Calls | 12,727,055▲ 3.66% |
| Total Puts | 10,433,481▼ 8.37% |
Holdings and activity of institutional investors.
| Ownership % | 61.41%▼ 1.02% |
|---|---|
| Total Invested | $68.02B▲ 12.61% |
| Investors Holding | 2,520▲ 83.00% |
No data
This committee provides crucial non-partisan analysis and official revenue estimates for all tax legislation. Its technical expertise directly influences the tax policies that are critical to Altria's financial performance and business strategy.
This powerful committee controls taxation (e.g., federal excise taxes on tobacco products, corporate income tax) and trade policy, which are critically important factors directly impacting Altria's revenue, cost structure, and profitability.
This committee has direct oversight of the FDA, which is the primary federal regulator for tobacco products. Its decisions profoundly impact Altria's product development, marketing, sales, and new product approvals (e.g., reduced-risk products).